GILD — GILEAD SCIENCES

Gilead Sciences commands the dominant position in HIV treatment — 51% of U.S. market share, $20.8 billion in HIV revenue growing at 6-8% annually, and patent protection on its flagship drug Biktarvy through 2036 — yet trades at roughly 16 times normalized pre-tax earnings, just above the threshold where the price stops requiring future growth to justify it. The company's newly approved twice-yearly HIV prevention injection, Yeztugo, represents a genuine new category with 100% efficacy in trials and a potential addressable population of over a million Americans currently without adequate prevention options, but near-term commercial momentum has been damaged by PEPFAR funding cuts that destroyed the testing and delivery infrastructure in the primary international target markets. Interesting, but it requires demonstration of Yeztugo commercial traction to be compelling at current prices.

---

The pharmaceutical industry is living through a structural repricing of its relationship with the U.S. government. The Inflation Reduction Act put Medicare in the business of negotiating drug prices, and the first results — 36% average price cuts on the initial negotiated drugs — have validated the program's intent in Washington while concentrating minds at every company whose blockbuster generates nine-figure annual Medicare revenue. The second round of drugs selected for 2028 negotiations includes Biktarvy, Gilead's $14 billion HIV franchise anchor, meaning the most valuable pharmaceutical franchise outside oncology and obesity now faces a government price ceiling within two years. That political fact shadows every other analytical question about Gilead: how durable is the moat when the payer with the most leverage has declared it will extract price concessions?

The IRA backdrop has reshaped how investors categorize large-cap pharma. Companies whose franchises are so clinically entrenched that pricing pressure reduces returns at the margin without threatening the underlying volume trajectory are treated differently from companies where pricing pressure risks substitution or formulary displacement. The distinction matters enormously for valuation. Gilead is the most instructive case study of what that entrenchment looks like in practice — and whether it is sufficient.

Beyond the IRA, the political environment has introduced a second, less anticipated complication. The U.S. government cut approximately 30% of global PEPFAR funding in early 2025, including a 90% reduction in South Africa's USAID-funded HIV programs. PEPFAR had been the infrastructure backbone for Gilead's most ambitious commercial launch in years — Yeztugo, the twice-yearly HIV prevention injection — in the markets where unmet need is largest. The cuts did not merely reduce a revenue line; they dismantled the testing and delivery networks that generate the eligible patient population in the first place. 4.7 million fewer people were tested for HIV in the affected countries in the twelve months following the cuts, a 22% reduction. Without testing, there is no PrEP eligible population. Without an eligible population, Yeztugo cannot demonstrate the commercial velocity that would justify extrapolating its extraordinary trial results to market projections.

The global HIV antiretroviral market is approximately $38 billion annually, growing at a 4 to 5% compound rate driven by treatment guideline expansions, improving PrEP uptake in high-income countries, and an ongoing transition from older oral regimens to newer once-daily fixed-dose combinations and long-acting injectables. The structural characteristics of this market are nearly ideal for the incumbent. 40.8 million people worldwide are living with HIV; 31.6 million are currently on antiretroviral therapy — 77% coverage — but once a patient starts a suppressive regimen and achieves viral undetectability, that patient rarely switches. The reason is clinical: virologic suppression is the treatment goal, and interrupting or altering an effective regimen risks viral rebound and resistance emergence. This creates a market with switching costs embedded in the biology of the disease rather than in software contracts or vendor relationships.

Three companies hold the meaningful positions. Gilead commands approximately 32% of global market share and over 51% of U.S. treatment-naive prescriptions. ViiV Healthcare — the GSK, Pfizer, and Shionogi joint venture — holds 24%. Merck holds approximately 15% through integrase inhibitor products. The remaining share is fragmented. The structural dynamic is that all three compete primarily for new diagnoses, since the existing suppressed patient population rarely switches. Each new HIV diagnosis is effectively a lifetime customer for whoever wins the initial prescription. New drug launches win by offering improved tolerability, convenience, or resistance barriers — not by displacing existing suppressed patients. This makes clinical data publication cycles, guideline committee votes, and long-acting innovation the primary competitive battlefield rather than price wars or distribution.

The long-acting injectable category is the most significant structural shift in two decades of HIV treatment. The paradigm of daily oral medication is being disrupted by injections requiring visits every two months in the case of ViiV's Cabenuva, or every six months in the case of Gilead's lenacapavir. For HIV prevention specifically — the PrEP market — this is a larger transformation than for treatment, because daily oral pill adherence in the prevention population has historically been a significant failure mode. A twice-yearly injection removes the adherence burden entirely and creates a prevention category whose real-world efficacy approaches what controlled trials demonstrated.

Gilead built its current franchise on the back of two prior revolutions. It transformed HIV treatment in the early 2000s with single-tablet regimens that replaced multi-pill cocktails, and it transformed hepatitis C treatment in 2014 through 2016 with Sovaldi and Harvoni, which cured the disease and generated $19 billion in peak annual revenue — before curing its own customer base and watching HCV revenue collapse nearly to zero within three years. That HCV experience, simultaneously one of the great pharmaceutical achievements and corporate planning failures, explains a great deal about how Gilead deploys capital today. The company has spent more than $50 billion on acquisitions since 2017, almost entirely in pursuit of oncology assets designed to diversify away from a franchise that, like HCV before it, will eventually face patent expiration and competitive erosion.

The current Gilead reports $29.4 billion in annual revenue, with approximately 71% derived from its HIV franchise and the remainder divided among oncology cell therapies and Trodelvy, liver disease treatments, and a declining COVID antiviral. This 71% concentration is the defining fact about the company: simultaneously the source of its enormous free cash generation and its central strategic vulnerability. The business Gilead is trying to build for 2030 is more diversified. The business generating cash today is still overwhelmingly an HIV company.

The moat within the HIV franchise is real, specific, and visible in the numbers. Biktarvy — the combination of bictegravir, emtricitabine, and tenofovir alafenamide — commands approximately 51% of the U.S. HIV treatment market. Five-year real-world follow-up data presented at EACS 2025 showed 97.9% viral suppression in treatment-naive patients and 96.8% in treatment-experienced patients, with no treatment-emergent resistance detected in clinical trials or real-world data through 168 weeks. That resistance-free record is not a marketing claim. It is a biological property of bictegravir's unusually high resistance barrier — the key mechanistic advantage that distinguishes it from prior integrase strand transfer inhibitors and makes substitution clinically inadvisable for stable suppressed patients.

Company / Product	U.S. Market Share	Key Differentiation	Primary Competitive Threat to Gilead
Gilead (Biktarvy)	~51% treatment	Highest resistance barrier INSTI; 97.9% suppression at 5 years with zero resistance emergence	—
ViiV Healthcare (Dovato)	Growing new-start share	2-drug regimen; less weight gain vs. Biktarvy in PASO DOBLE 2025 trial	New-start prescriptions for metabolically sensitive patients
ViiV (Cabenuva / Apretude)	~25% overall ViiV HIV share	Monthly/bimonthly injectable; superior injection site tolerability; 90% patient preference over lenacapavir in tolerability surveys	Long-acting injectable segment
Merck (Isentress-based)	~15% global	Established INSTI backbone products	Minimal — losing share to newer agents

ViiV's challenge to Biktarvy comes from two directions. Dovato's data showing meaningfully lower weight gain than Biktarvy in the October 2025 PASO DOBLE trial may shift some new-start prescriptions toward 2-drug regimens for patients where metabolic effects are the primary clinical concern. ViiV's injectable Apretude shows 90% patient preference over lenacapavir in tolerability surveys, driven by fewer and less severe injection site reactions with the intramuscular cabotegravir format. These are real competitive inroads at the margin. What they are not: threats to the approximately 1 million U.S. patients currently virologically suppressed on Biktarvy. The clinical cost of disrupting a successful regimen is real enough that physicians rarely recommend switching a stable suppressed patient, which means the competitive battle is almost entirely about winning new diagnoses rather than displacing the existing base.

The more important competitive dynamic is in PrEP, where Yeztugo was approved in June 2025 as the first twice-yearly HIV prevention injection, achieving 100% efficacy in the PURPOSE 1 and PURPOSE 2 trials across multiple geographies and demographic groups. That efficacy figure is the kind of clinical result that changes prescribing permanently once the healthcare infrastructure adapts to it. An injectable achieving 100% efficacy given twice per year competes against an oral pill requiring daily adherence at 90 to 95% real-world efficacy — and adherence in the PrEP population is the single largest determinant of prevention effectiveness. Yeztugo wins in any situation where adherence is a concern, which describes most of the addressable population.

Revenue for 2025 was $29.4 billion, up 2% from 2024. The headline growth rate obscures the underlying trajectory: the Medicare Part D benefit redesign under the IRA created a one-year $1.1 billion headwind in 2025 as the benefit structure changed, and Veklury revenue declined by approximately $400 million as COVID hospitalizations continued normalizing. Excluding these factors, the base business grew approximately 4 to 5%. HIV alone grew 6%, and the underlying volume-adjusted growth was closer to 10%. Product gross margins were 78.4%, characteristic of a franchise with genuine pricing power and no meaningful commodity cost exposure.

Free cash flow for 2025 was $9.5 billion, representing a 32% free cash flow margin on revenue. The balance sheet carries $25 billion in total debt against $10.6 billion in cash — net debt of $16.2 billion, approximately 1.7 times annual free cash flow. GAAP diluted EPS was $6.78; non-GAAP was $8.15. The gap between these figures is primarily amortization of acquired intangible assets — approximately $1.7 billion annually — stemming from the Immunomedics and Kite Pharma acquisitions. This is real economic cost in the sense that those acquisitions deployed capital, but it is a non-cash expense in the year it appears; the non-GAAP figure better represents the underlying franchise earnings power. The number management does not discuss prominently enough: the underlying HIV business grew at 10% in 2025 when adjusted for the Medicare Part D impact. That growth rate, on a $20.8 billion franchise, describes the core machine operating normally despite the pricing headwinds.

Daniel O'Day has run Gilead since 2019, arriving from Roche with a mandate to diversify beyond a franchise concentrated in HIV and a collapsing HCV business. His record on the HIV core is excellent: Biktarvy has grown from approximately $5 billion in revenue at the time of his appointment to $14.3 billion today, driven by consistent clinical data publication, guideline committee navigation, and commercial execution across treatment and prevention categories. Lenacapavir's development from a therapy for multi-drug resistant HIV through to twice-yearly PrEP approval represented one of the most technically complex regulatory and commercial sequences in recent pharmaceutical history, and O'Day's team executed it without the missteps that have derailed comparable platform expansions at peers.

The capital allocation record outside the HIV core is harder to defend. Gilead paid $11.9 billion for Kite Pharma in 2017 for CAR-T cell therapy; Kite's commercial arm generated $1.8 billion in 2025, down 7%, facing intensifying pressure from J&J and Legend Biotech's CARVYKTI, which approached $2 billion in annualized revenue in Q3 2025 alone. The Immunomedics acquisition in 2020 cost $21 billion for Trodelvy; Trodelvy generated $1.4 billion in 2025 — well below the $4 billion annual peak sales figure used to justify the acquisition price at the time, and still growing but from a base where the arithmetic of acquisition cost recovery is difficult. In early 2026, management deployed approximately $16 billion across three additional oncology acquisitions — Arcellx for $7.8 billion, Ouro Medicines for $2.2 billion, and Tubulis for $5 billion — all closing simultaneously in Q2 2026, creating integration complexity across three distinct platforms: cell therapy, autoimmune biology, and antibody-drug conjugate chemistry.

Each acquisition is individually defensible in strategic terms. Cumulatively, $51 billion in deployed acquisition capital generating approximately $5 billion in annual revenue from those assets — against a cost of capital implying roughly $3.5 billion in annual carrying cost — is a spread that requires significant additional growth from assets that have underperformed acquisition-time projections. The HIV franchise is subsidizing an oncology bet that has not yet earned its keep. Dividends are $3.28 per share annually at a 2.5% yield, and Gilead launched a new $6 billion share repurchase program in 2025. Capital is being returned to shareholders; the question is whether the $9.5 billion free cash flow engine is sufficient to fund all three priorities simultaneously — and on current numbers, it is, with limited margin for further slippage.

Year	Biktarvy Revenue	HIV Franchise Total	Oncology Revenue	Free Cash Flow
2022	$10.4B (+15%)	$17.1B	~$2.1B	$8.3B
2023	$11.9B (+14%)	$18.2B (+6%)	$2.9B (+38%)	$7.4B
2024	$13.4B (+13%)	$19.6B (+8%)	$3.3B (+14%)	$10.3B
2025	$14.3B (+7%)	$20.8B (+6%)	~$3.2B (flat)	$9.5B

Three things are visible in this table. Biktarvy's growth has decelerated from 13 to 15% annually to 7% in 2025, driven primarily by the Medicare Part D headwinds rather than underlying demand deterioration — management confirmed underlying volume growth remained closer to 10%. Whether the deceleration stabilizes at 6 to 8% or continues toward lower single digits as IRA pricing compounds is the central question for the franchise's remaining value. HIV franchise total revenue grows more slowly than Biktarvy because older products are declining at the base as patients migrate to newer regimens. The oncology revenue line has effectively stalled — cell therapy declining, Trodelvy growing modestly — which is the franchise that $51 billion in acquisitions was supposed to transform into the next growth engine. On a dollar basis, the oncology bet has yielded approximately $3.2 billion in annual revenue as of 2025.

The penetration argument for Yeztugo is the most compelling element of the growth runway. Approximately 591,000 Americans are currently on oral PrEP — roughly 49% of the 1.2 million adults the CDC estimates are eligible based on HIV risk factors. The remaining 609,000 eligible individuals are the primary untouched population for Yeztugo. At approximately $25,000 per year in U.S. list price, converting even 200,000 additional patients to twice-yearly injectable PrEP implies $5 billion in potential additional annual U.S. revenue. The global picture is structurally important but commercially secondary: 40.8 million people live with HIV globally, 9.2 million remain untreated, and generic Yeztugo at $40 per patient per year will serve the low-income country population through licensed generic manufacturers starting in 2027 — meaningful for public health, immaterial for Gilead's revenue line. The commercial thesis lives or dies on U.S. domestic uptake, which is entirely independent of PEPFAR and reachable through existing HIV clinic infrastructure.

At $133 per share, Gilead trades at a market capitalization of approximately $170 billion and an enterprise value of roughly $186 billion including net debt. Free cash flow of $9.5 billion yields 5.6% on market cap. Normalized pre-tax earnings — adjusting GAAP net income upward for the effective tax rate of approximately 17% — imply pre-tax earnings per share of approximately $8.15. At $133, the stock is priced at 16.3 times normalized pre-tax earnings, just above the threshold where you stop paying for future growth and start acquiring the franchise at a demonstrable discount.

The IRA impact in 2028 will be real and computable. Federal government spending on Biktarvy reached $3.9 billion in the year ending October 2025. The first round of Medicare price negotiations produced 36% average price cuts on the initial negotiated drugs. Even a 20% negotiated reduction on Biktarvy's Medicare exposure implies approximately $780 million in annual revenue compression starting 2028 — enough to offset roughly one year of underlying HIV franchise growth at current rates. The business does not stop compounding; it faces a price reset that will slow the earnings trajectory in 2028 and 2029. Patent protection through 2036 ensures volume durability; the IRA creates a pricing floor below which the government's negotiated price cannot go, but above which the company retains flexibility with private payers and international markets.

The intelligent bear on Gilead argues that the Yeztugo opportunity is structurally impaired in ways that will not recover: PEPFAR cuts have destroyed demand-generation infrastructure that a private company cannot rebuild; the $40 per year generic pricing in low-income countries makes the global prevention market commercially negligible; and U.S. market uptake will be structurally slow because twice-yearly injectable administration requires a healthcare visit that an oral pill does not — and HIV clinic capacity is already constrained. This argument deserves weight. The counter is that the U.S. commercial opportunity is entirely independent of PEPFAR, that the 609,000 unserved PrEP-eligible Americans are reachable through private HIV clinics and pharmacy-based administration models, and that a drug achieving 100% trial efficacy against a daily pill with real-world adherence failures wins the market whenever clinicians and patients prioritize prevention certainty over administrative convenience. The PURPOSE trial sites validating that efficacy included U.S.-based populations; the clinical infrastructure exists domestically. The question is velocity, not direction.

What would change the conclusion: Yeztugo demonstrating meaningful U.S. prescription volume in the first two commercial quarters would provide sufficient evidence that the HIV prevention franchise is expanding the addressable market rather than merely diversifying within it. At that trajectory, the Yeztugo contribution to HIV franchise revenue would begin offsetting the IRA headwinds on the existing portfolio, and the case for the stock at current prices would strengthen. Absent that evidence in the near-term reporting cycle, the investment is a good business at a fair price without a clear catalyst to move the multiple. The buy price at which the math becomes unambiguous — where the normalized earnings franchise is acquired at the threshold multiple without paying for growth — is approximately $122, roughly 8% below the current price.

The HIV franchise is real. The moat is real. The Yeztugo opportunity is clinically validated and commercially large. The price requires that at least one of these compounds better than the current numbers suggest, in the near term, to be clearly compelling from here.